Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

被引：2
作者：
Tamura, Kenji
Hashimoto, Jun
Tsuda, Hitoshi
Yoshida, Masayuki
Yamauchi, Hideko
Aogi, Kenjiro
Shimizu, Satoru
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Inoue, Kenichi
Ohno, Shinji
Kuroi, Katsumasa
Sukigara, Tamie
Fujiwara, Yasuhiro
Andoh, Masashi
机构：
[1] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Breast, Tokyo, Japan
[3] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan
[4] Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan
[5] Natl Canc Ctr, Dept Pathol & Labs, Tokyo, Japan
[6] St Lukes Int Hosp, Dept Breast Surg Oncol, Tokyo, Japan
[7] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan
[8] Kanagawa Canc Ctr, Dept Breast Oncol & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Aichi Canc Ctr, Dept Breast Oncol, Nagoya, Aichi 464, Japan
[10] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan
[11] Chiba Canc Ctr, Chiba 2608717, Japan
[12] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan
[13] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan
[14] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[15] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan
[16] Natl Canc Ctr, Tokyo, Japan
[17] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
    Liu, Yin
    Fan, Lei
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    ONCOLOGIST, 2023, 28 (01) : 86 - +
  • [32] Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402).
    Masuda, N.
    Nakayama, T.
    Matsunami, N.
    Kashiwaba, M.
    Kamigaki, S.
    Yamamura, J.
    Anami, S.
    Takeda, M.
    Yasumura, Y.
    Taguchi, T.
    CANCER RESEARCH, 2009, 69 (02) : 251S - 251S
  • [33] Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology
    Fontaine, C.
    Cappoen, N.
    Renard, V.
    Vuylsteke, P.
    Van den Bulck, H.
    Glorieux, P.
    de Roodenbeke, D. t'Kint
    Dopchie, C.
    Decoster, L.
    Vanacker, L.
    De Greve, J.
    Awada, A.
    Wildiers, H.
    CANCER RESEARCH, 2017, 77
  • [34] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
    Jame Abraham
    André Robidoux
    Antoinette R. Tan
    Steven Limentani
    Keren Sturtz
    Ibrahim Shalaby
    Hope Alcorn
    Marc E. Buyse
    Norman Wolmark
    Samuel A. Jacobs
    Breast Cancer Research and Treatment, 2015, 152 : 399 - 405
  • [35] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
    Iwase, S.
    Yamamoto, D.
    Kitamura, K.
    Odagiri, H.
    Teramoto, S.
    Ohtani, S.
    Doi, T.
    Kinebuchi, K.
    Kuroda, Y.
    Nagumo, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
    Abraham, Jame
    Robidoux, Andr
    Tan, Antoinette R.
    Limentani, Steven
    Sturtz, Keren
    Shalaby, Ibrahim
    Alcorn, Hope
    Buyse, Marc E.
    Wolmark, Norman
    Jacobs, Samuel A.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (02) : 399 - 405
  • [37] Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam
    Vecchione, Andrea
    Knopp, Michael V.
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2014, 14 (04) : 228 - 234
  • [38] A Phase II Study of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel with or without Trastuzumab as Primary Systemic Therapy in Locally Advanced Breast Cancer
    Shimizu, Tadao
    Hirano, Akira
    Kamimura, Mari
    Ogura, Kaoru
    Kim, Naomi
    Watanabe, Osamu
    Kinoshita, Jun
    Kimura, Kiyomi
    Ogawa, Kenji
    Fujibayashi, Mariko
    ANTICANCER RESEARCH, 2010, 30 (11) : 4665 - 4671
  • [39] A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
    Jinno, H.
    Sakata, M.
    Hayashida, T.
    Takahashi, M.
    Mukai, M.
    Ikeda, T.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1262 - 1266
  • [40] Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy
    Owusu-Brackett, N.
    Scott, S.
    Yuca, E.
    Evans, K. W.
    Tapia, C.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
12345